HomeMedical DevicesIn-Vitro Diagnostics

In-Vitro Diagnostics Market Research Reports & Consulting

discount on Mnm

Market Reports

Title Published Price TOC Available

Lateral Flow Assay Market by Application (Clinical Testing (Pregnancy, Infectious Disease (Mosquito , Influenza, STI, Hepatitis, TB), Cardiac Marker, Lipid Test) Veterinary, Food Safety) Product (Reader, Kits) Technique, End User - Global Forecast to 2023

The global lateral flow assay market is projected to reach USD 8.7 billion by 2023 from USD 6.0 billion in 2018, at a CAGR of 7.7%. The prominent players in the global lateral flow assay market are Abbott Laboratories (US), F. Hoffmann-La Roche AG (Switzerland), Danaher Corporation (US), Siemens AG (Germany), Becton and Dickinson Company (US), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), QIAGEN N.V. (The Netherlands), PerkinElmer, Inc. (US), Hologic, Inc. (US), Merck Millipore (US), Quidel Corporaton (US), Abcam plc. (US), DCN Diagnostics (US), Surmodics, Inc. (US), BioPorto Diagnostics A/S (Denmark), Chembio Diagnostic Systems, Inc. (US), Polysciences, Inc. (US), Innova Biosciences Ltd. (UK), Microcoat Biotechnologie GmbH (Germany), Senova GmbH (Germany), Scienion AG (Germany), and Orasure Diagnostics (US).

November 2018 $ 5650 selected

Molecular Diagnostics Market by Application (Infectious Disease (Hepatitis, HIV), Oncology, Genetic Testing), Technology (PCR, DNA Sequencing & NGS), End User (Hospital/Academic Laboratory), Product & Service (Reagent, Software) - Global Forecast to 2023

The global molecular diagnostics market is projected to reach USD 11.54 Billion by 2023 from USD 7.10 Billion in 2017, at a CAGR of 8.4%. The base year considered for the study is 2017, and the forecast for the market size is provided for the period between 2018 and 2023. Growth in this market is primarily driven by the high prevalence of infectious diseases and various types of cancers, increasing awareness and acceptance of personalized medicine and companion diagnostics, growth in the biomarker identification market, and advancements in molecular techniques. The key players in the global molecular diagnostics market are Roche (Switzerland), Hologic (US), QIAGEN (Netherlands), Abbott (US), and Danaher (US).

May 2018 $ 5650 selected

Immunoassay Market by Product & Service (Reagents & Kits, Analyzers, Software), Technology (ELISA, Rapid Test), Platform (Radioimmunoassay), Specimen, Application (Infectious Diseases, Oncology, Cardiology), End User (Hospitals) – Global Forecast to 2023

The global immunoassays market is expected to reach USD 27.15 Billion by 2023 from USD 20.19 Billion in 2018, at a CAGR of 6.1%. The market growth is primarily driven by the increasing incidence of chronic and infectious diseases and technological innovations in immunoassays instruments. Key players in the immunoassays market include Roche (Switzerland), Abbott Laboratories (US), Siemens (Germany), Danaher Corporation (US), Sysmex Corporation (Japan), bioMérieux (France), Ortho Clinical Diagnostics (US), DiaSorin (Italy), QIAGEN (Netherlands), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), Merck (Germany), Bio-Rad Laboratories (US), Agilent Technologies (US), PerkinElmer (US), Quidel Corporation (US), Bio-Techne Corporation (US), and Mindray (China).

May 2018 $ 5650 selected

Sepsis Diagnostics Market by Technology (Microbiology, Molecular Diagnostic, Immunoassay, Biomarkers), Product (Blood Culture Media, Instruments), Method (Automated), Test Type (Lab, POC), Pathogen (Bacterial, Fungal), End-User - Global Forecast to 2023

The sepsis diagnostics market is expected to reach USD 564.1 Million by 2021 from USD 370.0 Million in 2016, at a CAGR of 8.8% during the forecast period. Rising geriatric population, growing number of surgical procedures, high incidence of hospital-acquired infections, and increase in the number of product approvals are supporting the growth of this market. However, lack of standard protocols and awareness as well as shortage of skilled staff are the major challenges in this market. The major players of the sepsis diagnostics market are bioMérieux (France), T2 Biosystems (US), Luminex (US), Thermo Fisher Scientific (US), Bruker (US), Abbott (US), Roche (Switzerland), Danaher (US), Becton, Dickinson, and Company (US), EKF Diagnostics (UK), Immunexpress (Australia), Response Biomedical (Canada), Axis-Shield Diagnostics (UK), CytoSorbents (US), and Mitsubishi Chemical Europe (Germany).

April 2018 $ 5650 selected

Cancer Biomarkers Market by Type (Protein Biomarker, Genetic Biomarker), Cancer Type (Breast, Melanoma, Leukemia, Lung), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnosis, Prognostics, R&D) - Global Forecast to 2022

Cancer biomarkers are substances or processes that are indicative of the presence of cancers in the human body. Biomarkers may be produced by the cancer tissue itself or by other cells in the body in response to cancer. They can be found in the blood, stool, urine, tumor tissue, or other tissues or bodily fluids. They enhance cancer detection and facilitate high-speed noninvasive diagnosis using genomics and proteomics. The global cancer biomarkers market is accounted for USD 10.31 Billion in 2016 and is expected to grow at a CAGR of 12.2% to USD 20.48 Billion by 2022 during the forecast period. The major players in the cancer biomarkers profiling technology market are Abbott (US), Affymetrix (US), Roche (Switzerland), Illumina (US), QIAGEN (Netherlands), Agilent (US), Thermo Fisher (US), Merck (US), Becton Dickinson (US), and Hologic (US).

October 2017 $ 7150 selected

Allergy Diagnostics Market by Products (Assay Kits, Immunoassay & Elisa Analyzers, Luminometers, Services), Allergens (Food, Inhaled, Drug), Tests (In Vivo, In Vitro), End Users (Hospital, Diagnostic Laboratory) - Global Forecast to 2022

The global allergy diagnostics market is expected to reach USD 5.74 Billion by 2022 from USD 3.49 Billion in 2017, at a CAGR of 10.5%. Key players in the allergy diagnostics market include Thermo Fisher Scientific Inc. (US), Siemens AG (Germany), Danaher Corporation (US), Omega Diagnostics Group PLC (UK), Hitachi Chemical Co., Ltd. (Japan), bioMérieux SA (France), Stallergenes Greer (UK), HOB Biotech Group Suzhou Co., Ltd. (China), HYCOR Biomedical (US), Lincoln Diagnostics, Inc. (US), EUROIMMUN AG (Germany), INDOOR Biotechnologies, Inc. (US), DR. FOOKE - Achterrath Laboratorien GmbH (Germany), R-Biopharm AG (Germany), GA Generic Assays GmbH (Germany), Tecan Trading AG (Switzerland), DST Diagnostische Systeme & Technologien GmbH (Germany), ROXALL Medical GmbH (Germany), ALK-Abelló A/S (Denmark), Astra Biotech GmbH (Germany), HAL Allergy Group (Netherlands), Theradiag (France), and Demeditec Diagnostics GmbH (Germany).

August 2017 $ 5650 selected

Companion Diagnostics Market by Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), Technology (PCR, IHC, NGS, ISH), End User (Pharmaceutical & Biopharmaceutical Companies, Reference Lab) - Global Forecast to 2022

The global companion diagnostics market is projected to reach USD 6.51 Billion by 2022 from USD 2.61 Billion in 2017, at a CAGR of 20.1%. The growth of this market is majorly driven by the factors such as improvements in regulatory guidelines, growing need for targeted therapies, rising cancer incidence across the globe, and increasing collaborations and partnerships for companion diagnostics test development. However, uncertain reimbursement scenarios in different countries such as the U.S., U.K., Japan, and Australia are expected to limit market growth. In 2016, F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (U.S.), and QIAGEN N.V. (Netherland) dominated the global companion diagnostics market.

August 2017 $ 5650 selected

In Vitro Diagnostics (IVD) Quality Control Market by Application (Immunoassay, Molecular Diagnostics, Microbiology, Hemostasis, Hematology), Source (Serum, Whole Blood, Urine), Type (Instrument Specific, Third Party Control) - Global Forecast to 2022

The global in vitro diagnostics (IVD) quality controls market is estimated to reach USD 1.04 Billion by 2022, growing at a CAGR of 3.5% during the forecast period of 2017 to 2022. Major players in this market are continuously focusing on securing higher market shares through product launches, expansions, agreements, partnerships, and acquisitions. The major players in the global IVD quality controls market are Bio-Rad Laboratories, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Randox Laboratories (U.K.), Roche Diagnostics Limited (Switzerland), Abbott Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), Siemens Healthcare (Germany), and Sysmex Corporation (Japan).

July 2017 $ 5650 selected

Blood Group Typing Market by Product (Consumable (Anti-sera), Instrument, Service), Test Type (ABO, Antigen, Antibody Screening, Cross Matching, HLA), Technique (Assay, PCR, Microarray, Massively Parallel Sequencing), End User - Global Forecast to 2021

The blood group typing market is projected to reach USD 3.12 Billion by 2021 from USD 1.95 Billion in 2016, at a CAGR of 9.8%. The increasing demand for blood and blood products, growing number of road accidents and trauma cases that necessitate blood transfusion, need for blood grouping during prenatal testing, and increasing usage of blood group typing in forensic sciences are the major factors fueling the growth of this market.

April 2017 $ 5650 selected

Anatomic Pathology Market by Product & Service (Instruments (Tissue Processing Systems, Microtome), Consumables (Reagent & Antibodies), Histopathology, Cytopathology), Application (Disease Diagnosis, Drug Discovery & Development) - Forecasts to 2021

The anatomic pathology market was valued at USD 16.2 Billion in 2016 and poised to grow at a CAGR of 6.1% between 2016 and 2021, to reach USD 21.9 Billion in 2021. Key players operating in the anatomic pathology market include F. Hoffmann-La Roche AG (Switzerland), Thermo Fisher Scientific (U.S.), Danaher Corporation (U.S.), Agilent Technologies (U.S.), Sakura Finetechnical Co., Ltd. (Japan), Quest Diagnostics Incorporated (U.S.), Laboratory Corporation of America Holdings (U.S.), and NeoGenomics Laboratories, Inc. (U.S.).

March 2017 $ 5650 selected

HIV Diagnosis Market by Test Type (Antibody (ELISA, Rapid, Western Blot), Viral Load, CD4 Count, Early Infant, Viral Identification, Product (Assay, Kit, Reagent, Instrument, Software, Services), End User (Hospitals) - Global Forecast to 2021

The HIV diagnosis market is projected to reach USD 3.88 Billion by 2021 from USD 2.35 Billion in 2016, at a CAGR of 10.5% from 2016 to 2021. Factors such as the growing worldwide prevalence of HIV/AIDS, increasing number of blood transfusions and blood donations, benefits offered by point-of-care instruments and kits, and increasing government initiatives are expected to drive the growth of the HIV diagnosis market worldwide.

March 2017 $ 5650 selected

Blood Screening Market by Technology (Nucleic Acid Amplification, (rPCR), ELISA, (CLIA, Fluorescence assay), Rapid Test, NGS, Western Blotting), Product (Instrument, Reagent & Kits, Software) & End User (Blood Bank, Hospital) - Global Forecasts to 2021

The global blood screening market consists of various technologies and products & services which are used in blood banks and hospitals for the screening of various TTIs. The blood screening market is expected to reach USD 2.80 Billion by 2021 from USD 1.76 Billion in 2016, at a CAGR of 9.7%. The major factors driving the growth of this market are increasing number of blood donations and blood donors and rising awareness regarding the safety of donated blood. In addition, increasing affordability and adoption of nucleic acid test (NAT) for blood screening, rising demand for donated blood, and increasing prevalence of infectious diseases are also driving the growth of this market.

January 2017 $ 5650 selected

Hemostasis/Coagulation Analyzer Market by Product (Clinical Laboratory & PoCT Analyzers), Consumables, Test (PT, Fibrinogen, APTT, ACT, D Dimer, Platelet Function), Technology (Mechanical, Optical, Electrochemical), End User (PoCT) - Forecast to 2021

The coagulation analyzer market is projected to reach USD 4.84 Billion by 2021 from USD 2.98 Billion in 2016, at a CAGR of 10.2% from 2016 to 2021. On the basis of product, the coagulation analyzer market is segmented into clinical laboratory analyzers & PoC testing analyzers. The clinical laboratory analyzers segment is expected to account for the largest share of the global coagulation analyzers market in 2016, owing to increasing incidence of cardiovascular and blood related diseases.

November 2016 $ 5650 selected

Respiratory Diagnostics Market by Product & Service (Instruments/Devices, Kits/Reagents), Test Type (Pulmonary Function Test, Imaging Test), Disease (TB, Lung Cancer, COPD), End User (Reference Laboratories, Physician Offices) - Global Forecast to 2021

The global respiratory diagnostics market is projected to reach USD 7.45 Billion by 2021 from USD 5.24 Billion in 2016, at a CAGR of 7.3% from 2016 to 2021. In this report, the global respiratory diagnostics market is broadly segmented by product and service, test type, disease, end user, and region.

November 2016 $ 5650 selected

Cardiac Marker Testing Market by Type (Troponin I & T, CK-MB, Myoglobin, BNP, hsCRP), Product (Reagent, Instrument), Method (Chemiluminescence, ELISA), Disease (Myocardial Infarction, Congestive Heart Failure), Testing (Lab, POC) - Global Forecast to 2021

The global cardiac marker testing market is projected to reach USD 3.50 Billion by 2021, at a CAGR of 8.8% in the forecast period (2016–2021). Factors such as growing incidences of cardiovascular diseases, the rapidly increasing geriatric population, growing funding from public–private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers are driving the growth of the cardiac marker testing market. However, factors such as technical problems related to sample collection and storage and issues related to regulatory and reimbursement systems are some of the key factors hampering the growth of this market.

October 2016 $ 5650 selected

Urinalysis Market by Product Type (Dipstick, Reagent, Analyzers, POC), Test Type (Biochemical, Sediment, Microscopic, Flow-Cytometric), Application (Diabetes, UTI, Kidney, Liver Disease, Pregnancy), End User (Hospitals, Diagnostic Labs) - Forecast to 2021

The global urinalysis market is expected to reach USD 1.91 Billion by 2021 from USD 1.32 Billion in 2016, at a CAGR of 7.6%. The global market is broadly classified into product type, test type, applications, end user, and region. The key players in the urinalysis market include Beckman Coulter (U.S.), Roche Diagnostics (Switzerland), Siemens AG (Germany), Sysmex (Japan) and Arkray, Inc. (Japan).

July 2016 $ 5650 selected

Blood Culture Test Market Size & Share by Application (Bacteremia, Fungemia), Product (Consumables, Instrument), Method (Automated, Manual), Technology (PCR, Microarray, Proteomic) & End User (Hospital Laboratories, Reference Laboratories) - Global Forecast to 2021

The overall market for blood culture test is projected to reach $4,768.9 million by 2021 from $3, 252.6 million in 2016, at a CAGR of 8.0% during the forecast period. The base year considered for the study is 2015 and the forecast for the market size of blood culture test is provided for the period between 2016 and 2021.This report aims to estimate the market size and future growth potential of the global market across different segments such as method, product, technology, application, end user, and region. Factors such as rising aging population, increase in product approvals and launches, growing number of sepsis cases, high incidence of bloodstream infections (BSI), increase in demand for rapid diagnostic techniques, and high prevalence of infectious diseases are driving the market growth of blood culture test.

July 2016 $ 5650 selected

HLA Typing for Transplant Market by Technology (SSO-PCR, SSP-PCR, NGS, Sanger’s Sequencing), Products & Services (Instruments, Reagents, Software), Application (Diagnostics, Research), End User (Hospitals, Academia, Diagnostic Center) - Forecast to 2021

The global HLA typing for transplant market is projected to reach USD 753.9 Million by 2021 from USD 535.0 Million in 2016, growing at a CAGR of 7.1% from 2016 to 2021. Market growth can be attributed to factors such as the rising number of solid organ, soft tissue, and stem cell transplantations; technological advancements in the field of organ transplantations; and increased funding, research grants, and public-private investments.

May 2016 $ 5650 selected

Biochips Market Size & Share by Type (DNA Chip (Genomics, Drug Discovery, Gene Expression) Lab-on-a-chip (IVD & POC, Proteomics), Protein Chips), Fabrication Technology (Microarrays, Microfluidics), End user (Academics Institutes, Diagnostics Centers) - Global Forecast to 2020

is 2015 and the forecast for the market size is provided for the period between 2015 and 2020. In the current market scenario, biochips are increasingly adopted in various applications in the field of genomics, drug discovery, and proteomics. In addition, the development of targeted and personalized medicines for the treatment of cancer and technological advancements in biochips are also supporting the growth of biochip products.

May 2016 $ 5650 selected

Radioimmunoassay Market by Type (Reagents & Kits, Analyzers), End User (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), and Geography - Global Forecast to 2020

Radioimmunoassay (RIA) is an in-vitro assay technique that is used to measure the concentration of antigens in blood. RIA encompasses the separation of protein from a mixture by using the specificity of antibody- antigen binding and their quantitation by using radioactivity. The global radioimmunoassay (RIA) market was valued at $345.2 Million in 2014 and is expected to reach $428.4 Million in 2020 at a CAGR of 3.5% from 2015-2020.

October 2015 $ 5650 selected

Clinical Chemistry Analyzer Market by Product (Systems & Reagents), Test Type (Basic Metabolic, Electrolyte, Liver, Lipid, Renal, Thyroid Function, Specialty Chemicals), End User (Hospitals, Laboratories, Academic Research) - Global Forecast to 2019

The global clinical chemistry analyzers market was valued at $8,965.00 million in 2014and is poised to grow at a CAGR of 5.52% between 2014and 2019, to reach $11,728.01 million in 2018.Rapid growth in the diagnostics market, increase in the healthcare spending, and increasing incidence in lifestyle disease will drive the growth of the clinical chemistry analyzers market. Furthermore, increasing awareness for preventative healthcare, increase in aging population, increase in reagent rental agreements and increasing demand for laboratory automation will aid the demand for clinical chemistry analyzers products.

October 2014 $ 5650 selected

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 

Live Chat Support

US : 1-888-600-6441
UK : 44-800-368-9399

Search reports

M&M Custom Research Services provides clients with the information on their business scenario required to stay ahead of competition in today's fast paced business environment.
'Connect With Us

Call us at: 1-888-600-6441
Live Chat Support

Access reports on all high
growth In-Vitro Diagnostics Markets on KnowledgeStore
Request Demo